Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: canakinumab, lutikizumab, gevokizumab +2 | 0.90 |
| trials ClinicalTrials.gov | 15 Parkinson's trials, 3 stopped | 0.84 |
| literature PubMed | 57 Parkinson's papers of 7,614 | 0.47 |
| pathways Reactome | 10 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2440
Sealed predictions
- IL1B in dopamine neurons, braak-0.45 (p 0.230) → -0.63 (p 0.067)receipt 2447
Swarm cases
receipt 2447: IL1B in dopamine neurons, braak
- power
- full sample -0.32 (p 0.201, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.239, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.039, n 18). not the mix.
- skeptic
- leave-one-out range -0.46 to -0.23, sign flips 0; without severely affected donors -0.32 (p 0.201, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL1B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts